StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30127% above fair value
$21.73−0.98 (-4.32%)

Close on Nov 20, 2026Market cap $3.66BP/E –Yield –

Tango Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Tango Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$144.25M. For fiscal 2025 it was -$139.93M. The highest annual figure on record is $68.97M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$139.93M–
FY2024Dec 31, 2024-$132.26M–
FY2023Dec 31, 2023-$119.51M–
FY2022Dec 31, 2022-$116.77M–
FY2021Dec 31, 2021-$61.36M-189.0%
FY2020Dec 31, 2020$68.97M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$38.85M–
Q1 FY2026Mar 31, 2026-$44.36M–
Q4 FY2025Dec 31, 2025-$29.94M–
Q3 FY2025Sep 30, 2025-$31.10M–
Q2 FY2025Jun 30, 2025-$37.14M–
Q1 FY2025Mar 31, 2025-$41.75M–
Q4 FY2024Dec 31, 2024-$36.77M–
Q3 FY2024Sep 30, 2024-$33.51M–
Q2 FY2024Jun 30, 2024-$23.93M–
Q1 FY2024Mar 31, 2024-$38.05M–
Q4 FY2023Dec 31, 2023-$27.69M–
Q3 FY2023Sep 30, 2023-$31.15M–
Q2 FY2023Jun 30, 2023-$25.14M–
Q1 FY2023Mar 31, 2023-$35.53M–
Q4 FY2022Dec 31, 2022-$29.31M–
Q3 FY2022Sep 30, 2022-$22.89M–
Q2 FY2022Jun 30, 2022-$33.35M–
Q1 FY2022Mar 31, 2022-$31.23M–
Q4 FY2021Dec 31, 2021-$17.60M–
Q3 FY2021Sep 30, 2021-$22.27M–
Q2 FY2021Jun 30, 2021-$7.72M–
Q1 FY2021Mar 31, 2021-$13.78M–
Q4 FY2020Dec 31, 2020-$18.52M–

More Tango Therapeutics figures

See a number that looks wrong?